4 August 2022

Oxford Cannabinoid Technologies Holdings plc

Filing of Annual Report and Accounts

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF, "OCT" or the "Group") the pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market, announces that it will today file its Annual Report and Accounts for the 11 month period ended 30 April 2022.

The Annual Report and Accounts will shortly be uploaded to the National Storage Mechanism ("NSM") and will be available at: www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism. 

The Annual Report and Accounts is also available on the Company's website at: https://www.oxcantech.com/investors and in hard copy to shareholders upon request to the Company Secretary at Prama House, 267 Banbury Road, Oxford, England, OX2 7HT.

As announced on 25 July 2022, the Company's Annual General Meeting ("AGM") will be held at the offices of Penningtons Manches Cooper LLP at 125 Wood Street, London EC2V 7AW on 28 September 2022 at 11.30 a.m. The Notice of AGM will be sent to shareholders and made available on the NSM in due course.

The Directors of the Company take responsibility for the contents of this announcement.

Enquiries:

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc is the holding company of Oxford Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues, and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed in a solid oral dosage form. OCTP is conducting pre-clinical testing and development with clinical trials scheduled for Q1 2023. The Group's product pipeline also uses a balanced drug product strategy that employs both natural and synthetic compounds for the treatment of rare diseases and includes chemically modified phytocannabinoids with improved drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial partners.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.